Quark to fund new trial of ophthalmic RNAi drug partnered with Pfizer
This article was originally published in Scrip
Quark Pharmaceuticals says it has obtained "encouraging" results from a Phase II trial of the RNAi treatment, PF-04523655 (RTP801I-14), in patients with diabetic macular oedema (DMO). However, the study had to be terminated at 12 months after the interim analysis suggested that higher doses would be necessary to produce a therapeutic effect "sufficiently superior to the current standard of care to benefit patients over the long term given emerging new therapeutic modalities", explained Quark.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.